HR Execs on the Move

CIVCO Radiotherapy

www.civcort.com

 
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.civcort.com
  • 1401, 8th Street Southeast
    Orange City, IA USA 51041
  • Phone: 800.842.8688

Executives

Name Title Contact Details
Julia K
Chief Human Resources Officer Profile

Similar Companies

Apexigen, Inc

Apexigen, Inc. is a privately held biopharmaceutical company discovering and developing innovative antibody therapeutics for the treatment of life-threatening and difficult-to-treat diseases. Using its proprietary antibody technology platform, Apexigen has discovered a pipeline of product candidates, which are currently at varying stages of development. The lead product candidate, APX005M, is a novel immuno-oncology antibody that stimulates and enhances an immune response against cancer. Apexigen is developing other product candidates in partnership with four leading biopharmaceutical companies in China. In addition, Apexigen has formed strategic partnerships with multi-national pharmaceutical companies, including Janssen Biotech, Alcon Laboratories and Toray Industries to discover first-in-class antibody lead candidates for the partners' programs.

Diamatrix

Founded in 1993, Diamatrix helped usher in a new era of cataract surgery with its revolutionary Trapezoid diamond blade. Designed in conjunction with Clear Cornea pioneer, Dr. Charles H. Williamson, M.D. of the Williamson Eye Center in Baton Rouge, thi...

Neurana Pharmaceuticals

Neurana Pharmaceuticals is a privately held clinical stage San Diego based specialty pharmaceutical company developing a novel treatment for acute muscle spasms. The Company was founded in 2013 by veteran biotech entrepreneurs David F. Hale and Jeffrey Raser to focus on central nervous system (CNS) diseases and disorders.

Innocrin Pharmaceuticals

Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.

Fuse Medical

Fuse Medical, Inc., formerly Golf Rounds.com, Inc., is engaged in marketing, distributing and selling internal fixation, bone materials, biologics, tissues, surgical and other related surgical products. The Company operates through medical products and...